AAPS PharmSci360 Presentation: The Role of MIDD in Drug Development for COVID-19

On November 4, 2020 at the virtual AAPS conference, the role of model informed drug development practices as applied to COVID was discussed by Dr. Craig Rayner, President of Integrated Drug Development at Certara. It included commentary on the application of viral cell cycle models, epidemiological models, health economic models to guide treatment considerations.

It also included consideration of PKPD assumptions, the application of physiological based PK modelling, model based metanalyses and how insights derived from model based methods can inform clinical trial design, individual and combination treatment and regimen selection for COVID-19, timing of intervention within the disease course, likely impact on individual versus population health goals.

Leave a Reply

Your email address will not be published. Required fields are marked *